Search results for "hcv"

showing 10 items of 277 documents

Virological profiles in patients with chronic hepatitis C and overt or occult HBV infection

2002

Abstract OBJECTIVES: The virological profiles of hepatitis B and C viruses (HBV and HCV) and their interplay in cases of coinfection are undefined. A suppressed and occult HBV infection may occur in hepatitis B surface antigen (HBsAg) negative patients with chronic hepatitis C. The HCV core protein is able to inhibit HBV “in vitro,” and serines at positions 99 and 116 are essential for such inhibition. We aimed to assess the HBV and HCV virological profiles in cases of coinfection and to evaluate the relationship between HCV core gene variability and HBV activity. METHODS: Eighty-two anti-HCV positive patients were examined: 35 cases were HBsAg positive, 24 were HBsAg negative with “occult”…

AdultMaleHepatitis B virusHBsAgHCV RNAHepacivirusHepatitis C virusDUAL INFECTION; INTERFERON THERAPY; HEPATOCELLULAR-CARCINOMA; CHRONIC LIVER-DISEASE; HCV core protein; Hepatitis B Surface Antigens; HCV RNAGenome ViralHepacivirusDUAL INFECTIONVirus Replicationmedicine.disease_causeCHRONIC LIVER-DISEASEHepatitis B ChronicINTERFERON THERAPYOrthohepadnavirusHEPATOCELLULAR-CARCINOMAmedicineHumansAgedHepatitis B virusHepatitis B Surface AntigensHepatologybiologybusiness.industryHCV core proteinGastroenterologyvirus diseasesHepatitis C ChronicMiddle AgedViral LoadHepatitis Bbiology.organism_classificationmedicine.diseaseVirologydigestive system diseasesHepadnaviridaeDNA ViralImmunologyCoinfectionRNA ViralFemalebusinessThe American Journal of Gastroenterology
researchProduct

The histological or ultrasonographic detection of steatosis affects the performance of LSM in patients with chronic HCV genotype 1 infection

2014

Pathologymedicine.medical_specialtyHepatologyHcv genotype 1business.industryGastroenterologyMedicineIn patientSteatosisbusinessmedicine.diseaseDigestive and Liver Disease
researchProduct

Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions.

2013

Contains fulltext : 118153.pdf (Publisher’s version ) (Open Access) Hepatitis C virus (HCV) infected patients often take multiple co-medications to treat adverse events related to HCV therapy, or to manage other co-morbidities. Drug-drug interactions associated with this polypharmacy are relatively new to the field of HCV pharmacotherapy. With the advent of the direct-acting antivirals telaprevir and boceprevir, which are both substrates and inhibitors of the cytochrome P450 (CYP) 3A iso-enzyme, knowledge and awareness of drug-drug interactions have become a cornerstone in the evaluation of patients starting and continuing HCV combination therapy. In our opinion, an overview of conducted dr…

medicine.medical_specialtyCombination therapyPharmacologyAntiviral AgentsDrug interactionsTelaprevirTelaprevirchemistry.chemical_compoundPharmacotherapyAnti-Infective AgentsBoceprevirOpiate Substitution TreatmentmedicineHumansHypnotics and SedativesHypoglycemic AgentsPharmacokineticsSummary of Product CharacteristicsIntensive care medicineAdverse effectPolypharmacyBoceprevirHepatologybusiness.industryHCV therapyCardiovascular AgentsHepatitis C ChronicAntidepressive AgentsBuprenorphinechemistryCardiovascular agentHepatitis C virus infectionDrug Therapy CombinationHydroxymethylglutaryl-CoA Reductase InhibitorsPoverty-related infectious diseases Infectious diseases and international health [N4i 3]businessImmunosuppressive AgentsMethadonemedicine.drug
researchProduct

PEG IFN alfa-2a vs. alfa-2b: And the winner is …?

2009

Abstract Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS; IDEAL Study Team. N Engl J Med 2009 Aug 6;361(6):580–93. Background Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection. However, these regimens have not been adequately compared. Methods At 118 sites, patients who had HCV genotype 1 infection and who had not …

Hepatitismedicine.medical_specialtyHepatologybusiness.industryRibavirinvirus diseasesHepatitis Cmedicine.diseaseGastroenterologyChronic hepatitis HCV Head-to-head studies Pegylated interferons Ribavirindigestive system diseasesConfidence intervalSurgeryRegimenchemistry.chemical_compoundPharmacotherapystomatognathic systemchemistryTolerabilityInternal medicineMedicinebusinessAdverse effectJournal of Hepatology
researchProduct

Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort

2017

We evaluated the cost-effectiveness of two alternative direct-acting antiviral (DAA) treatment policies in a real-life cohort of hepatitis C virus–infected patients: policy 1, “universal,” treat all patients, regardless of fibrosis stage; policy 2, treat only “prioritized” patients, delay treatment of the remaining patients until reaching stage F3. A liver disease progression Markov model, which used a lifetime horizon and health care system perspective, was applied to the PITER cohort (representative of Italian hepatitis C virus–infected patients in care). Specifically, 8,125 patients naive to DAA treatment, without clinical, sociodemographic, or insurance restrictions, were us…

hepatitis C virusPediatricsCost effectivenessViral HepatitisAdult; Aged; Aged 80 and over; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Health Policy; Hepatitis C; Humans; Middle Aged; Young Adult; Models Economic; HepatologyCost-Benefit AnalysisDirect-acting antiviralAdult; Aged; Aged 80 and over; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Health Policy; Hepatitis C; Humans; Middle Aged; Young Adult; Models EconomicCohort StudiesLiver disease0302 clinical medicineModelsHealth careantiviral therapy80 and overincremental cost-effectiveness ratiohealth care economics and organizationsHCV cost -effectivenessAged 80 and overDirect-acting antiviral hepatocellular carcinoma hepatitis C virus incremental cost-effectiveness ratio interferon quality-adjusted life-years sustained virological response willingness to payCost–benefit analysis030503 health policy & servicesquality-adjusted life-yearsHealth PolicyHepatitis Chepatocellular carcinomainterferonMiddle AgedHepatitis CModels EconomicAdult; Aged; Aged 80 and over; Antiviral Agents; Cohort Studies; Cost-Benefit Analysis; Health Policy; Hepatitis C; Humans; Middle Aged; Young Adult; Models Economic; Hepatology; HCV; antiviral therapy; cost-effectiveness; real-life cohortCohortHCV030211 gastroenterology & hepatologyOriginal Articlesustained virological response0305 other medical scienceCohort studyHumanAdultmedicine.medical_specialtyEconomicAntiviral AgentsNO03 medical and health sciencesYoung Adultreal-life cohortmedicineHumansCost-Benefit Analysicost-effectivenessHealth policyAgedAntiviral AgentHepatologybusiness.industryOriginal Articlesmedicine.diseaseSurgeryCohort Studiebusinesswillingness to pay
researchProduct

Cardiovascular diseases and HCV infection: a simple association or more?

2013

HCV infection, metabolic disorders and cardiovascular alterations, considered alone or in combination, are common conditions in a large proportion of the general population. Consequently, determining whether the association of HCV infection with cardiometabolic disorders is simply coincidental or, conversely, caused by pathogenetic mechanisms (in)directly linking chronic HCV infection to these disorders, would be of extreme relevance. Several clinical studies have shown that metabolic disorders—namely, type 2 diabetes,1 insulin resistance (IR)2 and hepatic steatosis3—are highly prevalent in patients with chronic hepatitis C (CHC) compared with non-infected patients. Experimental and clinica…

education.field_of_studyVery low-density lipoproteinCholesterolPopulationGastroenterologyHeartHepatitis C ChronicBiologyAtherosclerosismedicine.diseasechemistry.chemical_compoundHigh-density lipoproteinInsulin resistancechemistryCardiovascular DiseasesDiabetes mellitusLow-density lipoproteinImmunologymedicineHumansMetabolic syndromehcv cardiovasculareducationGut
researchProduct

LIVER RELATED EVENTS AND SURVIVAL IN PATIENTS WITH COMPENSATED HCV CIRRHOSIS: THE ROLE OF SUSTAINED VIROLOGICAL RESPONSE TO PEG-IFN BASED THERAPY AND…

2011

HCV Cirrhosis SVR PEG IFN PORTAL HYPERTENSION
researchProduct

Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver Disease

2019

Background: Untreated, chronic hepatitis C virus (HCV) infection may lead to progressive liver damage, which can be mitigated by successful treatment. This integrated analysis reports the safety, efficacy, and pharmacokinetics (PK) of the ribavirin-free, direct-acting, antiviral, fixed-dose combination of glecaprevir/pibrentasvir (G/P) in patients with chronic HCV genotype 1-6 infections and compensated liver disease, including patients with chronic kidney disease stages 4 or 5 (CKD 4/5). Methods: Data from 9 Phase II and III clinical trials, assessing the efficacy and safety of G/P treatment for 8-16 weeks, were included. The presence of cirrhosis was determined at screening using a liver …

CyclopropanesLiver CirrhosisMaleAminoisobutyric AcidsPyrrolidinesCirrhosisSustained Virologic Responseadverse eventHepacivirusmedicine.disease_causeGastroenterology0302 clinical medicine030212 general & internal medicinePathologie maladies infectieusesSulfonamidesmedicine.diagnostic_testLiver DiseasesPibrentasvirMicrobiologie et protistologie [entomologiephytoparasitolog.]Infectious DiseasesData Interpretation StatisticalLiver biopsyglecaprevir/pibrentasvirHCVDrug Therapy CombinationFemale030211 gastroenterology & hepatologycompensated cirrhosisMicrobiologie et protistologie [parasitologie hum. et anim.]Microbiology (medical)medicine.medical_specialtyGenotypeProlineLactams MacrocyclicHepatitis C virusAntiviral Agents03 medical and health sciencesLeucineQuinoxalinesInternal medicinemedicineHumansAdverse effectAgedbusiness.industryGlecaprevirHepatitis C Chronicmedicine.diseaseBenzimidazolesMicrobiologie et protistologie [bacteriol.virolog.mycolog.]Transient elastographybusinesschronic kidney diseaseKidney diseaseClinical Infectious Diseases
researchProduct

Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients.

2013

Background and aims: Lower 25-Hydroxyvitamin D (25[OH]D) serum lev- els have been associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients (G1CHC). In addition, a recent genome-wide study identified genetic variants (rs12785878, near dehydrocholesterol reduc- tase, DHCR7; rs10741657, near CYP2R1; and rs7041, near vitamin D binding protein, GC) affecting 25(OH)D serum levels in healthy populations. We aimed to assess the association between vitamin D serum levels and its genetic determinants, with the severity of liver fibrosis. Material and methods: Two hundred sixty patients with biopsy-proven G1CHC were consecutively evaluated. The 25(OH)D serum levels wer…

VitaminAdultLiver CirrhosisMaleSerummedicine.medical_specialtyOxidoreductases Acting on CH-CH Group DonorsGenotypeHepatitis C virusSingle-nucleotide polymorphismHepacivirusBiologyReductasemedicine.disease_causeGastroenterologychemistry.chemical_compoundFibrosisVirologyInternal medicineGenotypemedicineVitamin D and neurologyHumansVitamin DCytochrome P450 Family 2Chromatography High Pressure LiquidHCV VITAMIN D DHCR7Settore MED/12 - GastroenterologiaPolymorphism GeneticHepatologyVitamin D-Binding ProteinHepatitis C ChronicMiddle Agedmedicine.diseaseInfectious DiseaseschemistryImmunologyCholestanetriol 26-MonooxygenaseFemaleSteatosisJournal of viral hepatitis
researchProduct

Comorbidities impact and de-prescribing in elderly with HCV-related liver disease: analysis of a prospective cohort.

2021

AbstractManagement for HCV has undergone a notable change using direct-acting antiviral drugs (DAAs), which are safe and effective even in elderly. Here, we define impact of comorbidities, concomitant medication and drug–drug interactions in elder patients with HCV related disease before starting DAAs regimen. We analyzed data of 814 patients prospectively enrolled at our Unit within the web based model HCV Sicily Network. Out of 814, 590 were treated with DAAs and 414 of them were older than 65 years. We divided those 414 in two groups, one including 215 patients, aged between 65 and 74 years, and another with 199 patients, aged of 75 years and over. Charlson Comorbidity Index (CCI) was as…

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaComorbidityHepacivirusDDI int eractionAntiviral AgentsCo-morbiditieDe-prescribing03 medical and health sciencesLiver diseaseElderly0302 clinical medicineQuality of lifeInternal medicineDiabetes mellitusInternal MedicinemedicineHumans030212 general & internal medicineProspective StudiesProspective cohort studyDepression (differential diagnoses)Agedbusiness.industryCharlson IndexHepatitis C Chronicmedicine.diseaseRegimenHCVEmergency MedicineQuality of Life030211 gastroenterology & hepatologyFemalebusinessDyslipidemiaKidney diseaseInternal and emergency medicine
researchProduct